Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the refacto market?

In recent times, the refacto market has seen XX (HCAGR). From 2024 to 2025, it is projected to expand from $XX million to $XX million, demonstrating a compound annual growth rate (CAGR) of XX%. The surge in this historic period is credited to factors such as a rise in the adoption of ERGs, the need for retail pharmacies, heightening awareness and diagnosis of hemophilia, an increased interest in self-administration, and growth in biosimilars.

What will be the refacto market size in the future?

In the coming years, the refacto market size is projected to expand by XX (FCAGR). By 2029, it is speculated to inflate to $XX million, with a compound annual growth rate (CAGR) of XX%. The anticipated growth during the forecast period can be linked to the increasing occurrences of LSDs, escalating oral cancer cases, a surge in hemophilia B instances, growing acceptance of prophylactic treatments, and an increase in chronic and intricate diseases. Notable trends during this period encompass progress in biotechnology and gene therapy, invention in drug formulation, technological progress in clotting factor products, breakthroughs in gene therapy and gene editing, and technological enhancements in production and manufacturing processes.

Get your refacto market report here!

https://www.thebusinessresearchcompany.com/report/refacto-global-market-report

What main drivers are fueling expansion in the refacto market?

The increasing occurrence of hemophilia A is predicted to fuel the expansion of the refacto market. Hemophilia A is a hereditary bleeding disorder caused by a lack or malfunction of clotting factor VIII, resulting in deficient blood clot formation and leading to extended bleeding even from minor injuries or spontaneously in severe conditions. The escalating cases of hemophilia A are attributed to enhanced diagnosis, heightened awareness, improved healthcare accessibility, and advancements in genetic screening and therapy, resulting in more identification and worldwide management of cases. Refacto (moroctocog alfa) aids in the treatment of hemophilia A by compensating for the inadequate clotting factor VIII, assisting in preventing or managing bleeding events and handling bleeding during surgeries. For example, in October 2022, a report from the World Federation of Hemophilia, a non-profit organization based in Canada, revealed that in 2022, 427,685 individuals globally were diagnosed with bleeding disorders. This included 257,146 hemophilia cases (208,957 of hemophilia A, 42,203 of hemophilia B, and 5,986 of an unspecified type), 100,505 cases of von Willebrand disease, and 70,034 cases of other bleeding disorders. Thus, the growing occurrence of hemophilia A is propelling the growth of the refacto market.

What key areas define the segmentation of the global refacto market?

The refacto market covered in this report is segmented –

1) By Clinical Indication: Prophylaxis; On-Demand Treatment; Perioperative Management; Immune Tolerance Induction (ITI)

2) By Formulation: Powder For Injection; Pre-Filled Syringes

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies

4) By End User: Pediatric; Adult; Geriatric

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20273&type=smp

Who are the dominant players expanding their reach in the refacto market?

Major companies operating in the refacto market are Pfizer Inc.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20273

Which regions are emerging as leaders in the refacto market?

North America was the largest region in the refacto market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the refacto market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Bleeding Disorder Testing Global Market Report 2025

https://thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report

Cyclic Heavy Menstrual Bleeding Global Market Report 2025

https://thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report

Bleeding Disorders Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: